a mechanistic understanding of HIV-1 latency depends on a model system that recapitulates the in vivo condition of latently infected, resting cD4 + t lymphocytes. latency seems to be established after activated cD4 + t cells, the principal targets of HIV-1 infection, become productively infected and survive long enough to return to a resting memory state in which viral expression is inhibited by changes in the cellular environment. this protocol describes an ex vivo primary cell system that is generated under conditions that reflect the in vivo establishment of latency. creation of these latency model cells takes 12 weeks and, once established, the cells can be maintained and used for several months. the resulting cell population contains both uninfected and latently infected cells. this primary cell model can be used to perform drug screens, to study cytolytic t lymphocyte (ctl) responses to HIV-1, to compare viral alleles or to expand the ex vivo life span of cells from HIV-1-infected individuals for extended study.
IntroDuctIon
The major barrier to curing HIV-1 infection is the latent reservoir. This reservoir predominantly comprises a small pool of CD4 + T lymphocytes (CD4s) that are in a resting memory state and harbor a stably integrated, replication-competent HIV-1 provirus. These latently infected cells are phenotypically indistinguishable from uninfected cells, and, consequently, they are difficult to target for elimination. Latently infected cells occur at a frequency of ~1 in 10 6 resting CD4s and have a half-life of ~44 months (refs. [1] [2] [3] [4] [5] . Thus, the reservoir is extremely stable, and infected individuals must receive lifelong treatment with antiretroviral therapy (ART) to inhibit viral propagation. Fortunately, current antiretroviral drug regimens are highly effective and have far fewer side effects compared with earlier drugs used to treat the infection. Although the life expectancy of an HIV-1-positive individual adhering to an effective ART regimen is similar to that of an uninfected healthy person 6 , not all infected individuals have the same adherence or access to necessary treatment. Treatment interruption can lead to viral rebound within weeks, even for infected individuals who have maintained undetectable viral loads 7 . Furthermore, it is not yet known whether treatment with ART that spans decades will cause adverse effects. As a result, there is much effort to find a cure for HIV-1 infection.
The focus of cure research has been on purging the latent reservoir. One approach, called 'shock and kill' 8, 9 , involves reactivation of viral expression by a latency reversing agent (LRA) and subsequent viral clearance. The expectation is that global reactivation of viral gene expression would result in elimination of the reactivated cells by immune mechanisms or viral cytopathic effects (CPEs), whereas the antiretroviral drug regimen of the treated individual would prevent viral spread. After serial rounds of reactivation, the hope is that the reservoir would ultimately be eradicated.
Development of the protocol and comparison with other methods
Effective reactivation of HIV-1 from latency is predicated on an understanding of how latency is established and maintained.
The study of latency using cells from infected individuals is complicated by the extremely low frequency of latently infected cells. The need to obtain sufficient numbers of CD4s from HIV-1-infected individuals limits the breadth and frequency of experiments that can be performed. In addition, variation from patient to patient, as well as variation within the same patient (e.g., drug adherence, drug regimen and so on), can complicate the analysis of certain types of experiments. Therefore, there is a great need for reliable in vitro models of HIV latency. In these models, the frequency of latently infected cells may be higher than is seen in vivo. This allows examination of a greater number of experimental conditions and permits better measures of the reproducibility or toxicity of a particular treatment. One of the principles guiding cure research is the necessity for finding LRAs that do not induce global T cell activation, which causes clinical toxicity. Cell models are advantageous because potential toxicity, which may be due to cytokine release, can be easily assessed.
Early in vitro models were based on immortalized, proliferating T lymphoblast lines such as Jurkat and SupT1 that were infected with HIV-1 or HIV-1/GFP reporter viruses. These cell lines have been informative in identifying potential factors that may contribute to latency, such as integration site and epigenetic state 10, 11 . However, transformed cell lines, even those that are derived from CD4s, are critically distinct from latently infected cells present in vivo because of their proliferative nature; they do not recapitulate the quiescent state of latently infected, resting CD4s. Another shortcoming of cell lines is their clonal nature, which means that the proviral integration site is identical in every cell. Thus, studies of integration site-dependent variability would require other approaches. These cell lines are still a vital tool in analyses that require vast numbers of cells, e.g., genome-wide studies and proteomics 12, 13 , but they are not optimal for studying the in vivo mechanisms of HIV-1 latency in resting memory CD4s.
For this reason, other efforts to establish models for HIV latency have used freshly isolated CD4s from healthy donors. These cells are infected in vitro with HIV-1 under various conditions, some of which differ from the way in which latency is probably established in vivo [14] [15] [16] [17] [18] [19] (for a review, see Spina 20 ). The model developed by Bosque and Planelles 18 involves the infection of primary naive CD4s that have been polarized by growth factors and antibodies to induce differentiation into central memory cells 21 . Another model created by the O'Doherty laboratory 15 and developed by the Greene laboratory 19 also calls for direct infection of resting CD4s by spinoculation. In the primary cell model designed by the Lewin laboratory 16 , resting CD4s are treated with chemokines to make these typically nonpermissive cells permissive to infection. The benefit of these primary cell models is that they all exhibit substantial frequencies of cells with integrated HIV-1 DNA and can be used in viral reactivation assays in about 1 week after infection. A caveat with models involving direct infection of resting CD4s is that the infection is inefficient and not all of the viral genomes may be integrated. In contrast, the models in which infection is preceded by activation do not allow sufficient time for the cells to return to a fully resting state. Furthermore, many of these primary cell models are limited by the short ex vivo life span of CD4s.
Here we describe a primary cell model that more closely approximates the condition of latently infected CD4s in HIV-1-infected individuals. This model solves the problem of the short ex vivo life span of CD4s by transducing cells with the B cell lymphoma 2 gene (Bcl2) (ref. 17) . Latency can then be established on a time scale that mimics physiological CD4 activation, infection and return to a resting state.
The process begins with the isolation of CD4s from healthy donors and it involves two rounds of lentiviral infection after activation through T cell receptor (TCR) engagement. Isolated CD4s are plated in medium containing antibodies to CD28 on a surface that is precoated with antibodies to CD3. Dual binding of the antibodies to CD3 and CD28 initiates intracellular signaling cascades that turn on expression of genes required for cytokine secretion, proliferation and differentiation-all hallmarks of T cell activation. Resting CD4s are relatively nonpermissive to infection, and this natural activation produces a cell state that is receptive for HIV-1 infection. In the first round of infection, activated CD4s are transduced with a lentivirus-expressing antiapoptotic Bcl2. The expression level of Bcl-2 in these cells is similar to that in freshly isolated CD4s (ref. 17 ; Fig. 1) , and it extends the life span of the cells ex vivo. Thus, the cells can be infected with an HIV-1 reporter virus after another round of activation, and then they can be cultured without exogenous cytokines for several weeks to allow a return to a resting state in which HIV-1 latency is established.
Applications and variations of the method
The Bcl-2 model has been used in screens to search for drugs and drug classes that induce the expression of latent HIV-1 (refs. 17,22-25) . In this protocol, for the second infection, we describe the use of a replication-deficient HIV-1/GFP reporter virus called CM6 (ref. 17 ; Fig. 2 ), which expresses only Tat, Rev and GFP. This virus was designed to assess drug effects on the activation of the 5′ long terminal repeat (LTR; which functions as the promoter) without inducing viral CPEs. The env gene is disrupted by insertion of a destabilized, enhanced GFP, and all other loci (gag, pol, vif, vpr, vpu and nef) are mutated to eliminate their expression. By using this reporter virus in one such screen, disulfiram was identified as a putative LRA, and the study of this drug advanced to clinical trials 22, 26 . In addition, the Bcl-2 model cells were used in identification of quinolines as another group of putative LRAs 23 . Our laboratory continues to use these cells to screen drug libraries for potential LRAs or classes of drugs that may stimulate viral expression from the 5′ LTR.
Although we have used CM6 to study drug effects on viral expression, this virus could also be used to look at the effects of overexpression or knockdown of endogenous cellular proteins on viral gene expression; Bcl-2 model cells could be nucleofected with a construct that constitutively expresses a protein of interest, or that expresses shRNA to a protein of interest. The cells could then be easily assayed for viral activation by measuring GFP positivity by flow cytometry.
Both viruses in this protocol are pseudotyped with VSV-G envelope, which has a broad tropism and is associated with high stability in resulting virions; however, wild-type envelope could be substituted if, for example, a particular co-receptor tropism were being studied.
As the virus used in the second round of infection can be uniquely engineered, the investigator has the flexibility to examine many facets of viral expression. In addition, the second-round virus need not be a reporter virus. For example, if one wished to study the differences between alleles of gag or env, a single, expanded batch of Bcl-2-transduced cells could be infected with a panel of viruses that each differed in one of those loci. The effects of those sequence differences on protein function in virion assembly or entry, respectively, could then be measured. If one were interested in looking at specific points in the life cycle of infection, one could, for instance, generate viruses that had mutations in RT, integrase or protease. This could also be achieved by using drugs that inhibit these enzymes, but a virus mutationally null in any of these loci would obviate the need to continually add drugs over the course of an assay. Bcl-2 model cells can also be used to study 'shock and kill' approaches to viral eradication, despite the antiapoptotic function of Bcl-2. Its overexpression in model cells does not preclude viral CPE, as shown in work by Shan et al. 27 . To examine the death of infected cells after reversal of latency, Shan et al. Because it is an effective method for extending the ex vivo life span of primary CD4s, the Bcl-2 model also enables examination of the long-term effects of particular treatments or viruses.
An additional cell sorting step can be inserted in this protocol to enrich the resulting population for latently infected cells. After Step 79, the GFP + cells can be selected by flow cytometric sorting before the subsequent 4-6-week incubation without exogenous cytokines (Step 80). Although this enrichment step increases the frequency of latently infected cells overall (from ~2 to ~30%), the final yield of cells is far lower, resulting in the same absolute number of latently infected cells 17 . Nonetheless, this population of cells that is enriched for latent infection offers a larger dynamic range and better signal-to-noise ratio for studies of potential LRAs.
Limitations
Owing to the CPEs of productive HIV-1 infection and the comparatively low frequency of latent infection, the final yield of latently infected cells in this model is modest. As noted above, an additional cell sorting step immediately after reporter virus infection increases the percentage of latently infected cells, although with a lower absolute number of cells. We are currently developing a modification to the Bcl-2 model using constructs similar to reporters developed by Dahabieh et al. 28 and Calvanese et al. 29 . This modification will increase both the frequency of latent infection and the absolute number of cells produced. The CM6 reporter virus described in this protocol contains GFP in the env open-reading frame (Fig. 2) , and green fluorescence indicates HIV-1 gene expression that only occurs when the HIV-1 5′LTR is activated. To this CM6 HIV-1/GFP reporter virus, we add a second fluorescent marker monomeric Kusabira Orange (mKO), which is constitutively expressed. In the final cell sorting (Step 84), selection of cells that are GFP − and mKO + will isolate the cells that are latently infected. This will be a pure population, as the expression of mKO reflects successful infection; in the absence of a second fluorescent marker, the GFP − population contains a majority of cells that were never infected.
The total time required to produce one batch of Bcl-2 model cells is 12-14 weeks. One step that can be shortened is the Bcl-2 transduction step; we are developing a Bcl-2-transducing virus that carries the puromycin resistance gene (Pm R ). This virus would ensure that every cell that is transduced also has Pm R such that, at Step 49, the incubation will be decreased from 3 weeks to 1 week by puromycin resistance selection. This circumvents the need to wait for nontransduced cells to exhaust their natural ex vivo lifetime. Another way to expedite the protocol is to freeze expanded Bcl-2 cells, as described in Step 65. The expansion (Steps 57-65) can yield up to 10 9 Bcl-2 cells; cells that are not used right away can be stored frozen and thawed as needed, and they can be used immediately in part III of the protocol.
Biohazardous materials. HIV-1 is a class 2 human pathogen, and infectious HIV-1 should be handled in a biosafety level 2 (BSL-2) facility. The described and produced in this protocol cannot establish a spreading infection; however, we observe guidelines that are in accordance with BSL-3 practices when working with these viruses. Liquid waste is inactivated by bleach, and all waste is autoclaved before disposal. 
Experimental design
This protocol to establish the primary Bcl-2 model cells comprises three major parts, and it has convenient pause points after parts I and II. The following subsections briefly describe each part.
Part I (3 d). Virus production (Steps 1-18).
Viruses needed to generate latently infected cells are produced using a three-plasmid packaging system 30, 31 . Two types of viruses are made ( Fig. 3) : one is the Bcl-2-encoding transducing virus (from pEB-FLV) and the other is an HIV-1/GFP reporter virus (from pCM6) that is not replication competent. Steps 1-18 must be performed twice to make both viruses. We prepare DNA for transfection using an endotoxin removal kit such as NucleoBond Xtra Maxi EF from Clontech to ensure the highest transfection efficiency. By using Lipofectamine 2000 from Life Technologies according to the manufacturer's instructions, we transfect HEK293T cells with a plasmid mixture. In addition to either pEB-FLV or pCM6, the transfection complexes include a packaging helper plasmid (pCHelp) and a VSV-G envelope pseudotyping plasmid (pVSV-G); pC-Help and pVSV-G are required for viral packaging and single-round infection 31 . After incubating the transfected HEK293T cells for 48 h, we clarify the supernatant (which contains the virus) and pellet the virions by ultracentrifugation over a 20% (wt/vol) sucrose cushion. Virus can be produced concomitantly with the start of part II, or it can be produced in advance and stored at −80 °C until needed.
Part II (5.5 weeks). Isolation of healthy donor CD4s, Bcl-2 transduction and expansion (Steps 19-65).
CD4s are isolated from 120 ml of blood from a healthy donor by Ficoll density gradient centrifugation and negative selection over a magnetic column. CD4s are subsequently activated by TCR engagement and infected with the Bcl-2-transducing virus produced in part I. Transduced cells are selected by removing dead cells through another Ficoll density gradient centrifugation that is performed on a smaller scale than with the initial whole blood; we call this a 'mini Ficoll'. Once isolated, the transduced cells are activated and expanded by incubation with IL-2 for 7-10 d (Fig. 4) . After expansion, which can result in an increase of up to 1.5 logs, Bcl-2 cells can be frozen at −80 °C and stored for later use.
Part III (5.5 weeks). HIV-1/GFP reporter virus infection and isolation of Bcl-2 model cells (Steps 66-89).
Expanded Bcl-2-transduced cells are activated by TCR engagement and infected with the HIV-1/GFP reporter virus produced in part I. After infection, the cells are incubated without exogenous cytokines for several weeks to allow a return to a resting state. GFP − cells are isolated by flow cytometric sorting after the culturing period (Fig. 5) . The spinoculation in this part is nearly identical to Steps 39-55 in part II. The primary differences are that we are spinoculating Bcl-2 cells instead of CD4s, and that we are using the CM6 HIV-1/GFP reporter virus instead of the EB-FLV Bcl-2-transducing virus. After spinoculation, we let the cells rest for 4-6 weeks in the absence of exogenous cytokines before sorting for GFP negativity at a BSL-2 cell sorting facility. Before use, we measure the frequency of latently infected cells in a test reactivation using phorbol 12-myristate 13-acetate (PMA) and ionomycin. If the Bcl-2 model cells are not used within 4 weeks of cell sorting, we perform a mini Ficoll to remove the dead cells before experimental use. 
MaterIals
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Box 1 | TCGF preparation • tIMInG 11 d
About 1 week before we plan to make TCGF, we order four LeukoPaks from the New York Blood Center (http://nybloodcenter.org/).
Request that the blood be tested to ensure that it is HIV-1 negative. The following steps can also be scaled down to prepare TCGF from one LeukoPak. In steps 8-11 below, the medium is removed by aspiration from flasks containing PBMCs, which are suspension cells; the PHA/PMA incubation causes most of the cells to become activated and clump together in aggregates that are generally adherent to the surface of the flask. We typically see only losses of ~15% of the cells cumulatively over all of the washes. Do not spin down the medium removed in each step to recover cells, as adding recovered cells back to the culture does not improve activity in our experience. 1. Prepare RPMI-HS by adding the following to each of two 500-ml bottles of RPMI: 5 ml of penicillin-streptomycin and 12.5 ml of heat-inactivated human serum type AB. 2. Isolate PBMCs by the standard Ficoll procedure (as in Steps 21-27 of the main PROCEDURE). On average, one LeukoPak will yield ~10 9 PBMCs, although we have seen a range of 0.5-1.5 × 10 9 PBMCs per LeukoPak. Typically, one can expect to isolate 4 × 10 9 PBMCs in this step. 3. For all of the isolated PBMCs, resuspend 400 million PBMCs per T-150 tissue culture flask in 70 ml of the RPMI-HS. 4. Incubate the flasks overnight at 37 °C. 5. To each T-150 flask containing 70 ml of PBMCs + medium, add 933 µl of PHA (150 µg/ml solution) for a final concentration of 2 µg/ml, and add 7 µl of PMA (50 µg/ml solution) for a final concentration of 5 ng/ml. 6. Incubate the flasks for 4 h at 37 °C. 7. While the flasks are incubating, prewarm WM and RPMI-HS at 37 °C. Depending on how many PBMCs were isolated in step 2, more RPMI-HS may have to be prepared. 8. Gently move the flasks from the incubator to the tissue culture hood. 9. Slowly tilt each flask so that it is upright (Fig. 6a) . Use a 2-ml aspirating pipette to carefully remove the culture supernatant. 10. Gently add 15 ml of warmed WM by slowly ejecting the fluid onto the inner top surface of each flask (Fig. 6b) , i.e., not onto the surface where the cells are resting. At a tilted angle, slowly rotate the flask 360° once (Fig. 6c) . Incubate the flasks for 10 min at 37 °C to let the cells settle again. 11. Repeat steps 8-10 twice for a total of three WM washes. These steps are to remove the PHA and PMA. 12. Gently add 70 ml of RPMI-HS to each flask by slowly ejecting the fluid onto the inner top surface of the flask (Fig. 6b) , i.e., not onto the surface where the cells are resting. 13. Incubate the flasks for 40 h at 37 °C. 14. To collect culture supernatants containing TCGF, transfer the supernatants from the flasks to 50-ml conical tubes and spin them at 1,455g for 10 min at 4 °C to remove cell debris. 15. Sterilize the supernatants, 500 ml at a time, over vacuum-driven 0.45-µm filtration units. 16 . Store the sterilized supernatants in 40-ml aliquots at −20 °C for up to 6 months. 17. To assay the amount of TCGF produced, see Box 2. FBS The serum arrives frozen in 500-ml bottles and is stored at −20 °C upon arrival. When needed, one bottle is thawed slowly overnight at 4 °C and heat-inactivated for 30 min at 56 °C. The heat-inactivated serum is then stored at 4 °C for up to 4 weeks.  crItIcal When purchasing FBS from Gemini Bio-products, we test several lots against each other in a cell proliferation assay, as described in Box 3. We select the lot that promotes the most cell proliferation and order enough bottles to make medium for 2 or 3 years.
HI-FBS
The serum arrives frozen in 500-ml bottles, and it is stored at −20 °C upon arrival. When needed, one bottle is thawed slowly overnight at 4 °C and stored at 4 °C for up to 4 weeks.  crItIcal When purchasing HI-FBS from Life Technologies, we use their reserve serum testing
program and test several lots against each other in a cell proliferation assay, as described in Box 3. We select the lot that promotes the most cell proliferation and order enough bottles to make medium for 2 or 3 years. Human AB serum The serum arrives frozen in 100-ml bottles, and it is stored at −20 °C upon arrival. When needed, one bottle is thawed slowly overnight at 4 °C and heat-inactivated for 30 min at 56 °C. The heat-inactivated serum is then stored at 4 °C for up to 4 weeks. Dextrose, 10% (wt/vol) Bring 100 g of dextrose to 1 liter with ultrapure water and dissolve it with stirring. Filter-sterilize it and store it at room temperature. 10% (wt/vol) dextrose is stable at room temperature for at least 1 year. Wash medium (WM) To make 1 liter of WM, start with 848 ml of ultrapure sterile water and add 10 ml of 10% (wt/vol) dextrose, 100 ml of 10× PBS, pH 7.4, 10 ml of penicillin-streptomycin (10 3 U/ml and 10 3 µg/ml), 12 ml of 1 M HEPES (pH 7.2), and 20 ml of HI-NBCS. Filter-sterilize the medium and store it at 4 °C for up to 4 weeks. Heparin Dissolve heparin in 1× PBS, pH 7.4, at a final concentration of 1,000 U/ml. Filter-sterilize it through a 0.2-µm filter and divide the solution into aliquots in 2-ml tubes. Store the heparin at 4 °C for up to 2 years. These stocks are 100×. IL-2 stock Reconstitute with 1.2 ml of ultrapure, sterile water and then add 98 ml of sterile WM to obtain a final stock concentration of 2.24 × 10 5 U/ml. Store the stock in 1-ml aliquots at −80 °C for up to 1 year. For the Bcl-2 cell expansion (Part II), thaw one vial of the IL-2 stock and add 1.24 ml of CFM. This is a 1,000× (10 5 U/ml) solution that will be stable for the duration of the expansion; it will be 100 U/ml when diluted 1:1,000.  crItIcal Whenever we reconstitute a new bottle of IL-2, we test the new IL-2 against the previous IL-2 in a cell proliferation assay, as described in Box 3, to ensure its effectiveness. PHA Resuspend 2 mg of the powder in 5 ml of WM and then add 8.3 ml more of WM to obtain a stock concentration of 150 µg/ml. Store it in 1-ml aliquots at −80 °C for up to 6 months. Once it is thawed, store it at 4 °C and use it within 2 weeks. PMA Resuspend 1 mg of the powder in 1 ml of sterile DMSO to obtain a stock concentration of 1 mg/ml. Store it at −20 °C in 50-and 5-µl aliquots for up to 6 months. For the TCGF preparation (Box 1), dilute 50 µl of the 1 mg/ml stock with 950 µl of WM for a final concentration of 50 µg/ml. To measure the frequency of latently infected cells (part III), dilute 5 µl of the 1 mg/ml stock with 995 µl of RPMI to obtain a final concentration of 5 ng/µl. The working solutions should be prepared just before use.
Box 2 | Cell proliferation assay to assess TCGF effectiveness • tIMInG 2-3 d
To assess the ability of the TCGF that was produced in the procedure described in Box 1 to support the growth of T cells, we use a cell proliferation assay. We test each new batch against the previous batch of TCGF; however, for first-time analyses, one can perform a titration series of STCM made with 0, 5, 6, 7, 8, 9 and 10 ml of the TCGF-containing medium made in Box 1. By using a colorimetric assay kit from Promega, we determine the minimum amount of TCGF addition that stimulates maximal cell growth. Each STCM/TCGF condition is tested in triplicate and requires 3 × 10 5 PBMCs; testing all seven conditions requires ~2.1 × 10 6 PBMCs. 
Box 3 | Cell proliferation assay to assess sera or IL-2 effectiveness • tIMInG 2-3 d
To measure the effectiveness of different lots of sera or to ensure the effectiveness of new batches of IL-2, we perform a cell proliferation assay using a colorimetric kit from Promega, as described in Box 2. To test sera, we prepare one bottle of STCM (as described in Reagent Setup) for each lot of serum that is to be tested. Likewise, to test IL-2, we prepare one bottle of STCM (as described in Reagent Setup) with the new, freshly reconstituted IL-2 and one bottle with the previous IL-2. We test sera lots or IL-2 batches in triplicate and measure the ability of the serum or IL-2 to stimulate cell growth. 10. We select the serum lot that promotes the most cell proliferation; every IL-2 batch we have tested has been at least as effective as the previous batch and is usually more effective.
concentration 100 U/ml) and 5-10 ml of TCGF (depending on TCGF preparation; see Box 2). Store the medium at 4 °C for up to 1 month and only as long as the pH indicator dye remains red (usually within 1-2 weeks); discard the medium if the pH indicator dye has turned purple. 6| Add the plasmid mixture to the Lipofectamine 2000 mixture and mix it. Incubate the transfection complexes for 5 min at room temperature.
7| Add ~4 ml of transfection complexes to each flask. ! cautIon After transfection, cells and supernatant contain lentiviral particles. Although neither of the viruses described in this protocol can establish a spreading infection, we treat all flasks and cells after this point as if they could. It is good practice to use the same precautions when you are working with any kind of virus.
8|
Incubate the cells for 48 h at 37 °C.
9| Pelleting virus.
Turn on the ultracentrifuge and prechill the vacuum chamber, rotor and swinging buckets.
10|
Prepare an ice bucket that will comfortably accommodate eight 50-ml conical tubes, and place it in the hood. Chill four 50-ml conical tubes and four Steriflip filter units on ice.
11| Divide the supernatant from the six flasks over the four chilled 50-ml conical tubes and pellet the debris at 335g for 3 min at 4 °C. When making the CM6 reporter virus, which contains GFP in the env locus, the transfection efficiency can be evaluated at this point by running a small aliquot of transfected 293T cells on a FACS instrument and by measuring the GFP + population. Typically, 10-40% of the 293T cells are GFP + .
12| Attach a Steriflip unit to each 50-ml conical tube, and invert the tube with vacuum to clarify the supernatant.
13|
Place six ultracentrifuge tubes on ice to chill. Divide the clarified supernatant over the six ultracentrifuge tubes.
14| By using a 2-ml serological pipette, slowly underlayer 2.5 ml of 20% (wt/vol) sucrose buffer.  crItIcal step Be careful not to disrupt the interface between the sucrose and the supernatant. Eject the sucrose solution using the slowest speed on the pipettor.
15|
Balance the ultracentrifuge tubes in pairs using a mechanical beam balance.
16|
Spin at 76,755g for 2 h at 4 °C.
17|
Place the ultracentrifuge tubes on ice and aspirate all of the liquid.  crItIcal step When aspirating, do not go near the bottom of the tube where the virus pellet rests. The virus pellet can be difficult to see, but when virus production is robust the pellet appears as a small, slightly beige and sticky mass at the base of the tube. ? trouBlesHootInG
18|
Resuspend the virus by adding 300 µl of CFM to each ultracentrifuge tube. Without creating bubbles, pipette the CFM over the pellet several times. Transfer the virus to two 2-ml screw-cap microcentrifuge tubes and freeze the tubes on a dry ice/ethanol bath. Store them at −80 °C.  crItIcal step We do not titer the virus because we continuously make model cells in our laboratory; we have found that, generally, the virus produced from one T-150 flask is sufficient to infect 10-15 × 10 6 activated CD4s.  pause poInt Virus can be produced in advance, frozen and stored at −80 °C for several years. Frozen aliquots of virus should only be thawed once before use to ensure maximal infectivity. 
20|
Prepare two 60-ml syringes with 600 µl of heparin (for a final concentration of 10 U/ml blood). In addition, ensure that the centrifuge for spinning 50-ml conical tubes is at room temperature.
21| Aliquot 15 ml of Ficoll-Paque PLUS into four 50-ml conical tubes (one Ficoll tube for every 30 ml of blood).
22| Aliquot 10 ml of WM into four 50-ml conical tubes (one WM tube for every Ficoll tube).
23|
After the blood is drawn, gently invert the syringes a few times to mix the heparin additive to prevent clotting.  pause poInt The blood in the syringes can be stored for up to 30 min in the 37 °C incubator; otherwise, proceed immediately to the next step. If you are pausing, be sure to mix the blood by inversion before layering onto the Ficoll, as separation of red blood cells (RBCs) and plasma may occur while the tubes rest in the incubator.
24|
By touching the tip of the syringe to the inside of the tube, slowly layer 30 ml of blood per tube already filled with 15 ml of Ficoll-Paque PLUS. Spin the tubes at 400g for 25 min at room temperature.
25|
After spinning, the emergent upper layer is the serum and the bottom layer is the Ficoll, granulocytes and RBCs. At the interface of serum and Ficoll is a white layer, called the buffy coat, which contains PBMCs. Aspirate 15-20 ml of serum, but do not disturb the buffy coat. By using a 10-ml pipette, insert the tip directly into the buffy coat and transfer the cells into the 50-ml conical tube pre-aliquotted with 10 ml of WM in Step 22. Bring the volume of each tube up to 40 ml with WM, and then pellet the PBMCs at 335g for 10 min at 4 °C.
26|
Aspirate the supernatant and add 1 ml of WM. Resuspend the cells thoroughly by pipetting up and down vigorously several times with a P1000 pipette. Pool the PBMCs into one 50-ml conical tube and bring the volume up to 40 ml with WM. Count an aliquot of the cells using a 1:10 dilution with trypan blue. We typically see 150-350 × 10 6 PBMCs isolated from 120 ml of blood. To facilitate the subsequent column selection steps, we make a multiplier chart based on the cell count. 
28|
Aspirate the supernatant and resuspend it in 4 µl per 10 6 PBMCs of WM (using the example in table 1, this would be 748 µl of WM).
29| Add 1 µl per 10 6 PBMCs of the biotin-antibody cocktail from the Miltenyi CD4 + T cell isolation kit (using the example in table 1, this would be 187 µl). Mix and incubate the cells for 5 min at 4 °C.
30| Add 3 µl of WM per 10 6 PBMCs (using the example in table 1, this would be 561 µl).
31| Add 2 µl of the anti-biotin microbeads from the Miltenyi CD4 + T cell isolation kit per 10 6 PBMCs (using the example in table 1, this would be 374 µl). Mix and incubate the mixture for 10 min at 4 °C.
32|
While the cells are incubating with the microbeads, prepare the LS columns. Use one column per 10 8 PBMCs.
Clean the MACS MultiStand and MidiMACS separator and place them in the hood. Open the LS column packages inside the hood and magnetically attach each column to the separator, taking care to maintain the sterility of the column tip. Prime each column with 3 ml of WM and discard the flow-through. Arrange a 50-ml conical tube in ice under each column for cell collection.
33|
When the microbead incubation is finished, add WM to bring the final volume of the cells to 3 ml per LS column and apply 3 ml to each column. The flow-through is the eluate containing the CD4s. Apply another 3 ml of WM to each column and pool all the eluates.
34|
Count an aliquot of the cells using a 1:4 dilution with trypan blue. Pellet the remaining CD4s at 335g for 10 min at 4 °C. ? trouBlesHootInG
35|
Resuspend the CD4s in STCM at a final concentration of 10 6 cells per ml.
36|
Add anti-CD28 antibody at a final concentration of 1 µg/ml.
37| Wash the anti-CD3 plates prepared in
Step 19 and then gently add the CD4s from Step 36 to the six-well plates, dividing the volume evenly across all wells.
38| Incubate the cells for 3 d at 37 °C to activate.
39| Spinoculation and selection of Bcl-2-transduced CD4s (Bcl-2 cells).
Ensure that the centrifuge for spinning 96-well plates is at room temperature. Check the CD4s in the six-well plates. If they have activated well, the color of the STCM will change from pink to yellow, and the cells will adhere to each other and form small clumps. Under the microscope, the cells will be much larger than unactivated cells. ? trouBlesHootInG 40| Prewarm ~15 ml of STCM to at least room temperature. Pool and count an aliquot of the cells using a 1:2 dilution with trypan blue. Pellet the cells at 335g for 10 min at 4 °C, and resuspend them in prewarmed STCM at a final concentration of 5 × 10 6 cells per ml.
41|
Thaw the Bcl-2 virus produced in part I (from Step 18) in a 37 °C water bath. Add the virus to the activated CD4s and mix it well. 
42|
Transfer the cell/virus mix to a sterile basin and add 100 µl (0.5 × 10 6 cells) per well of a 96-well round-bottom plate using a multichannel pipettor.
43|
Spin the plates at 1,200g for 2 h at room temperature.
44|
Add 100 µl of STCM to each well and pipette up and down to resuspend the cells.
45|
Incubate the cells overnight at 37 °C.
46|
Transfer the cells to a T-150 flask and supplement the volume with STCM as follows: the final volume here should be, in milliliters, double the number of millions of cells that were spinoculated. For example, if 50 × 10 6 cells were spinoculated, the final volume should be 100 ml; if 80 × 10 6 cells were spinoculated, the final volume should be 160 ml.  crItIcal step The optimal volume range for a T-150 flask is 30-75 ml. Use as many flasks as necessary to ensure that the volume per flask is within this range. 
52|
Resuspend up to 10 8 cells in 9 ml of the prewarmed CFM, and slowly layer the suspension over the Ficoll-Paque PLUS. Spin the tube at 335g for 10 min at room temperature.
53|
The cells that are transduced (i.e., alive) will settle at the interface between the CFM and the Ficoll. Carefully remove these cells with a P1000 pipette and transfer them to a 50-ml conical tube pre-aliquotted with 10 ml of WM. 57| Expanding Bcl-2-transduced CD4s. Add 1 µg/ml anti-CD28 antibody to the Bcl-2 cells.
58| Wash the anti-CD3 plates prepared in
Step 55 and then gently add the Bcl-2 cells from
Step 57 to the six-well plates, dividing the volume evenly across all wells.
59| Incubate the cells for 3 d at 37 °C to activate.
60| Check the CD4s in the six-well plates. If they have activated well, the color of the STCM will change from pink to yellow and the cells will adhere to each other and form small clumps. Under the microscope, the cells will be much larger than unactivated cells. Pool and count an aliquot of the cells. Pellet the cells at 335g for 10 min at 4 °C and resuspend them in CFM at a final concentration of 10 6 cells per ml.
? trouBlesHootInG 61| Add IL-2 (10 5 U/ml solution) at a 1:1,000 dilution to obtain a final concentration of 100 U/ml.
62|
Incubate the cells at 37 °C.
63|
Count the cells every other day. Supplement the volume with CFM to readjust the concentration to 10 6 cells per ml and add IL-2 at a 1:1,000 dilution based on the new volume. As the number of cells and volume increase, divide the cells over a sufficient number of flasks to ensure that the volume per flask is within the recommended range (see the Critical Step in
Step 46). The first few times that the cells are counted, they should triple; the next few times, they will only double. When the cells stop doubling, proceed to the next step. Usually, the expansion will take 7-10 d. ? trouBlesHootInG 67| Prewarm ~15 ml of STCM to at least room temperature. Pellet 60 × 10 6 Bcl-2 cells at 335g for 10 min at room temperature, and resuspend them in prewarmed STCM at a final concentration of 10 6 cells per ml. Add 60 µl of anti-CD28 antibody to obtain a final concentration of 1 µg/ml.
68|
When the anti-CD3 antibody-coating incubation is complete, wash the anti-CD3 plates prepared in Step 66 and then gently add the Bcl-2 cells from Step 67 to the six-well plates, dividing the volume evenly across all wells.
69| Incubate the cells for 3 d at 37 °C to activate them.
70|
Ensure that a centrifuge for spinning 96-well plates is at room temperature. Check the CD4s in the six-well plates. If they have activated well, the color of the STCM will change from pink to yellow and the cells will adhere to each other and form small clumps. Under the microscope, the cells will be much larger than unactivated cells.
71| Prewarm ~15 ml of STCM to at least room temperature. Pool and count the cells using a 1:2 dilution with trypan blue. Pellet the cells at 335g for 10 min at 4 °C and resuspend them in prewarmed STCM at a final concentration of 5 × 10 6 cells per ml.
? trouBlesHootInG 72| Thaw the HIV-1/GFP reporter virus produced in part I in a 37 °C water bath. Add the virus to the activated Bcl-2 cells and mix well.
73|
Transfer the cell/virus mix to a sterile basin and aliquot 100 µl (0.5 × 10 6 cells) per well of a 96-well round-bottom plate using a multichannel pipettor.
74|
Spin the plate at 1,200g for 2 h at room temperature.
75|
Add 100 µl of STCM to each well, and pipette up and down to resuspend the cells.
76|
77|
Transfer the cells to a T-150 flask and supplement the volume with STCM as follows: the final volume here should be, in milliliters, double the millions of cells that were spinoculated. For example, if 50 × 10 6 cells were spinoculated, the final volume should be 100 ml; if 80 × 10 6 cells were spinoculated, the final volume should be 160 ml.  crItIcal step The optimal volume range for a T-150 flask is 30-75 ml. Use as many flasks as necessary to ensure that the volume per flask is within this range (see the Critical Step in Step 46). 
78|
81|
Mini Ficoll the cells as described in Steps 50-54 to remove dead cells.
82|
Count the cells and resuspend them in CFM at a final concentration of 10 6 cells per ml.
83| Isolation of the latent cell-containing population (Bcl-2 model cells).
The parameters of this step will depend on the cell sorting facility used. In the facility we use, we are directed to resuspend our cells in WM at a final concentration of 30 × 10 6 cells per ml. We sort for a GFP − cell population that comprises both cells that were not infected and cells that are latently infected. Together, these are the Bcl-2 model cells. of two 1.5-ml microcentrifuge tubes. To one tube, add 3 µl of PMA (5 ng/µl solution) to obtain a final concentration of 50 ng/ml and 3 µl of ionomycin (100 µM solution) for a final concentration of 1 µM.  crItIcal step To determine the percentage of latent infection, we compare an aliquot of untreated model cells with an aliquot that is treated with PMA and ionomycin. We assay the levels of GFP expression with and without drug treatment on a FACS instrument. For both untreated and treated samples, divide 100 µl over three wells of a 96-well round-bottom plate.
86|
Incubate the cells for 24 h at 37 °C.
87|
Spin the plate at 335g for 10 min at 4 °C, carefully aspirate most of the medium and resuspend the cells in 100 µl of 1× PBS.
88|
Measure the GFP + cells on an FACS instrument. This is the frequency of latently infected cells. See Figure 8 for representative FACS data.
? trouBlesHootInG Troubleshooting advice can be found in table 2.
• tIMInG Virus production and initial isolation of CD4s can begin at the same time. We also stockpile virus so that it is not a limiting factor.
Virus production Day 1
Step Step 48, medium transfer: 1 h
Step 49, incubation and selection: 3 weeks
Day 28
Steps 50-54, 6 PBMCs from 120 ml of healthy donor blood after the Ficoll sedimentation spin and 60-90 × 10 6 CD4s after the column separation. After Bcl-2 transduction of 60 × 10 6 CD4s and the mini Ficoll in Steps 50-54, we consider an outcome of 10 × 10 6 Bcl-2 cells to be successful and sufficient to continue to the expansion. The amount of expansion that occurs will vary from donor to donor so that even if one batch only generates 10 × 10 6 Bcl-2 cells, the expansion could still result in 10 9 Bcl-2 cells. Once frozen (Step 65), most batches will exhibit 60-80% survival upon thawing within the first few months; thus, one batch can provide stock for numerous experiments. The percentage of latently infected cells that are established by this protocol ranges from 0.5-3%. Factors that largely influence this are the conditions of the 293T cells used for producing virus (i.e., virus quality) and the donor-to-donor variation of the Bcl-2 cell batches. We isolate the latent cell population 6 weeks after the HIV-1/GFP virus-infected cells are transferred to CFM. Again, owing to the aforementioned variation, we have seen batches generate 22-63 × 10 6 Bcl-2 model cells; on average, of the cells that we take to the cell sorting facility, more than two-thirds are GFP − .
